Skip to main content
USPHU.S. Physical Therapy, Inc.Sell4.7·$73.38+1.42%
SellModerate Confidence
Investment thesis

U.S. Physical Therapy offers 24% upside to analyst consensus targets and converts free cash flow at 124% of net income, but the company falls just below the $1 billion minimum market cap threshold for this investable universe, and a confirmed price downtrend combined with extremely elevated put-to-call options activity creates a difficult entry environment.

Thesis pillars

  • Analyst Target UpsideStable
  • Free Cash Flow ConversionStable
  • Downtrend Below 200maStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

U.S. Physical Therapy, Inc. (USPH) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Medical Care Facilities

Sell if holding. At $73.38, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Below 200-MA, MA slope -3.2%/30d (confirmed downtrend); Weak overall score: 4.7/10.

U.S. Physical Therapy operates through two segments: physical therapy clinics providing orthopedic, sports-injury, and worker rehabilitation services, and an industrial injury prevention (IIP) segment contracting directly with employers, including Fortune 500 companies. The... Read more

$73.38+11.1% A.UpsideScore 4.7/10#29 of 36 Medical Care Facilities
QualityF-score6 / 9FCF yield3.91%
IncomeYield2.52%(5y avg 1.82%)Payout362.00%at-risk
Stop $68.56Target $81.49(analyst − 13%)A.R:R 0.7:1
Analyst target$93.67+27.6%6 analysts
$81.49our TP
$73.38price
$93.67mean
$100

Sell if holding. At $73.38, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Below 200-MA, MA slope -3.2%/30d (confirmed downtrend); Weak overall score: 4.7/10. Chart setup: Death cross but MACD improving, RSI 73. Score 4.7/10, moderate confidence.

Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.

10-K grounded · weekly refresh

About U.S. Physical Therapy, Inc.

About U.S. Physical Therapy, Inc.

U.S. Physical Therapy owned and/or managed 780 clinics across 44 states at December 31, 2025, generating $650.4 million in net patient revenue, up from $560.6 million in 2024. Managed care and commercial health insurance supplied 48.5% of net patient revenue and Medicare/Medicaid another 35.8%, with workers' compensation insurance contributing 10.2%. The company's highest clinic concentration is in Texas, Tennessee, Michigan, New York, and Virginia, among other states.

U.S. Physical Therapy earns physical therapy revenue on a per-procedure, outpatient basis, generally structured through Clinic Partnerships in which the company holds a 65% to 75% typical equity stake (ranging 30% to 99%) alongside physical therapist partners who retain minority interests, receive base salaries, and can earn bonuses tied to their clinic's profitability. Departing partners' interests are subject to put and call rights priced at a predetermined multiple of clinic earnings. The IIP segment operates on a different model, contracting directly with employers, including a number of Fortune 500 companies, for onsite injury prevention, performance optimization, and ergonomic assessment services rather than billing third-party payors. Growth comes largely through acquisitions: the company completed multi-clinic transactions at ownership stakes ranging from 40% to 80% during 2023-2025, plus 14, 8, and 9 tuck-in clinic acquisitions in 2025, 2024, and 2023, respectively.

Show full overview

U.S. Physical Therapy's revenue is directly exposed to the annual Medicare Physician Fee Schedule cycle: the 10-K discloses MPFS reimbursement cuts of 3.5%, 0.75%, 2.0%, 1.8%, and 1.5% for calendar years 2021 through 2025, respectively, before an expected 1.75% increase in 2026. With Medicare and Medicaid patients accounting for 35.8% of net patient revenue and 40.1% of visits in 2025, a return to the multi-year pattern of MPFS cuts — which regulators have imposed in four of the last five years — would pressure per-visit economics more than a single bad year of managed-care contract renegotiations.

See also: Healthcare · Medical Care Facilities

From U.S. Physical Therapy, Inc.'s most recent 10-K filing, extracted July 6, 2026.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Aug 5, 202631d to earnings· next earnings call

Thesis

Rewards
Positive momentum
Risks
Weak overall score: 4.7/10
Below 200-MA, MA slope -3.2%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)144.7
P/E (Fwd)21.2
Mkt Cap$1.1B
EV/EBITDA17.0
Profit Mgn4.4%
ROE6.8%
Rev Growth7.9%
Beta1.14
Dividend2.52%
Rating analysts13

Quality Signals

Piotroski F6/9

Options Flow

P/C17.00bearish
IV75%elevated
Max Pain$60-18.2% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMregulatoryMedicare/Medicaid36%
    10-K Item 1: 'approximately 40.1% of our visits and 35.8% of our net patient revenue was from patients with Medicare or Medicaid program coverage'
  • MEDIUMCustomercommercial health insurers, HMOs, PPOs, and workers' compensation insurers
    10-K Item 1: 'Our physical therapy business depends to a significant extent on our relationships with commercial health insurers, health maintenance organizations, preferred provider organizations and workers' compensation insurers.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
0.0
Support Resistance
0.0
52w Position
6.0

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
1.8
Quality Rank
4.2
Growth Rank
5.7
GatesA.R:R 0.7 < 1.5@spotDeath cross (50MA < 200MA)Momentum 7.0>=5.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 31d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
73 · Overbought
20D MA 50D MA 200D MADEATH CROSSSupport $60.86Resistance $73.41

Price Targets

$69
$81
A.Upside+11.1%
A.R:R0.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! asymmetry at 0.7 (below the engine's 1.5 threshold)@spot

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-08-05 (31d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is USPH stock a buy right now?

Sell if holding. At $73.38, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Below 200-MA, MA slope -3.2%/30d (confirmed downtrend); Weak overall score: 4.7/10. Chart setup: Death cross but MACD improving, RSI 73. Prior stop was $68.56. Score 4.7/10, moderate confidence.

What is the USPH stock price target?

Take-profit target: $81.49 (+11.1% upside). Prior stop was $68.56. Stop-loss: $68.56.

What are the risks of investing in USPH?

Weak overall score: 4.7/10; Below 200-MA, MA slope -3.2%/30d (confirmed downtrend).

Is USPH overvalued or undervalued?

U.S. Physical Therapy, Inc. trades at a P/E of 144.7 (forward 21.2). TrendMatrix value score: 4.7/10. Verdict: Sell.

What do analysts say about USPH?

13 analysts cover USPH with a consensus score of 4.2/5. Average price target: $94.

What does U.S. Physical Therapy, Inc. do?U.S. Physical Therapy operates through two segments: physical therapy clinics providing orthopedic, sports-injury, and...

U.S. Physical Therapy operates through two segments: physical therapy clinics providing orthopedic, sports-injury, and worker rehabilitation services, and an industrial injury prevention (IIP) segment contracting directly with employers, including Fortune 500 companies. The company owned and/or managed 780 clinics across 44 states at year-end 2025, generating $650.4 million in net patient revenue primarily through majority-owned Clinic Partnerships with local physical therapists.

Related stocks: NUTX (Nutex Health Inc.) · UHS (Universal Health Services, Inc.) · SRTA (Strata Critical Medical, Inc.) · ARDT (Ardent Health, Inc.) · AVAH (Aveanna Healthcare Holdings Inc)
Home Stocks USPH

Latest news

Latest News

MarketBeat69d agoEarnings
Yahoo Finance62d agoEarnings
StockStory62d agoEarnings
Marketscreener.com62d agoEarnings
Yahoo Finance62d agoEarnings
StockStory63d agoEarnings
FinancialContent63d agoEarnings
Insider Monkey68d ago
Yahoo Finance62d agoEarnings
MSN65d ago
Newser71d ago
Benzinga5d agoProduct
Benzinga13d ago
Benzinga55d ago
Benzinga60d ago
Benzinga62d ago
Benzinga62d ago
Benzinga83d ago